Which peptides are in clinical trials but not FDA-approved?
Short answer
17 profiles here are in clinical trials and not FDA-approved, according to the sources their profiles cite.
Each entry below quotes its profile and links to the full answer there.
Metabolic and weight 11
In clinical trials; not FDA-approved12,13,14
Not FDA-approved. FDA states that cagrilintide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.14
Is cagrilintide FDA-approved? · Cagrilintide vs Semaglutide · Pramlintide vs Cagrilintide
In clinical trials; not FDA-approved17,18,19
Not FDA-approved. No FDA approval is reported in the sources reviewed here, and a phase 3 trial in type 2 diabetes is registered as recruiting.17,18
Is efpeglenatide FDA-approved? · Efpeglenatide vs Semaglutide
In clinical trials; not FDA-approved22,23,24
Not FDA-approved. Amgen has registered Phase 3 trials on ClinicalTrials.gov, including MARITIME-1 and MARITIME-CV.23,24
Is maridebart cafraglutide FDA-approved? · Maridebart cafraglutide vs Tirzepatide
In clinical trials; not FDA-approved25,26,27
Not FDA-approved. Three Phase 3 trials, including ZUPREME-4 and ZUPREME-5, are registered on ClinicalTrials.gov.26,27,28
Is petrelintide FDA-approved? · Petrelintide vs Cagrilintide
In clinical trials; not FDA-approved14,29,30
Not FDA-approved. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.14
Is retatrutide FDA-approved? · Tirzepatide vs Retatrutide · Semaglutide vs Retatrutide
In clinical trials; not FDA-approved14,31,32
Not FDA-approved. FDA lists survodutide among unapproved drugs it has warned companies for selling with false research-use labels.14
Is survodutide FDA-approved? · Survodutide vs Retatrutide · Survodutide vs Tirzepatide
Liver 1
Gut and digestion 3
Brain, nerves and sleep 1
Infections 1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Oral Amycretin in Japanese Men With Obesity · record history version 6 · last update posted 2025-03-05 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial (2026) · PMID 42532080 ↗
The Lancet · Official source · Source checked November 14, 2026
- 3ClinicalTrials.gov record NCT07668401 · retained source version 2026-08-24:5833a93b62ac59e564069a1fd4bf8cd19222029a0b3f7ce99899f59f22b177dc ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 4ClinicalTrials.gov record NCT07720271 · retained source version 2026-09-28:93ed8b5caeb775d7d6fbd3c0d4e0c5ce26698ea8c1ae70efd4b447411785d74d ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 5ClinicalTrials.gov record NCT07797335 · retained source version 2026-09-01:bc9e4b3246b2a07cc90834c13fa40cb6e95033b38aa14b8b29396518aff35b74 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 6ClinicalTrials.gov record NCT07861100 · retained source version 2026-10-06:c1032ee418d61646c75ff354e74a7285b9376c0eaeb82c0622036ec003177db0 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 7ClinicalTrials.gov record NCT07931495 · retained source version 2026-11-12:23a664ffa2bff21e8dd34305b3456a3ee5f65f216d24ab4d40b786451213bde4 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 8ClinicalTrials.gov record NCT07931547 · retained source version 2026-11-12:2d2f13db63aaf8b3fc36fdb710419bcd545343ee84a805e746017fc30430e350 ↗
ClinicalTrials.gov · Official source · Source checked November 15, 2026
- 9Avexitide acetate substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 10PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia (2021) · PMID 33616643 ↗
The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026
- 11Efficacy and safety of avexitide for treatment of hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study (2026) · PMID 42744082 ↗
Metabolism: Clinical and Experimental · Official source · Source checked November 15, 2026
- 12Cagrilintide and CagriSema in Children and Adolescents With Excess Body Weight · record history version 5 · last update posted 2026-07-17 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 13ClinicalTrials.gov record NCT07220759 · retained source version 2026-08-03:50fb10a6adbd81022c8cc1ee950e283b46f97533acbf5a944399ee4e77eaceb1 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 14FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 15Cotadutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 16Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study (2021) · PMID 34016612 ↗
Diabetes Care · Official source · Source checked November 15, 2026
- 17Efpeglenatide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 18ClinicalTrials.gov record NCT07379333 · retained source version 2026-05-13:c599578eaa8d429e0152e13caf981fed9266ac8441a80524f20f68e1f1aaac63 ↗
ClinicalTrials.gov · Official source · Source checked November 16, 2026
- 19Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 20Eloralintide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 21Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (2025) · PMID 41207310 ↗
The Lancet · Official source · Source checked November 15, 2026
- 22Bioavailability of AMG 133 in Participants With Overweight or Obesity · record history version 1 · last update posted 2026-07-21 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 23ClinicalTrials.gov record NCT06858839 · retained source version 2026-09-17:beb2c75eb0a3bc43ffe1b4c9fab269e89fcf8ae6cbe11f7d4c3ea4213aed3e04 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 24ClinicalTrials.gov record NCT07037433 · retained source version 2026-07-24:ae9704758762002a715a9ed9f57da8845f1a2ea224c8296b8200071653366d78 ↗
ClinicalTrials.gov · Official source · Source checked August 13, 2026
- 25Petrelintide With Enicepatide in Adults With Obesity or Overweight · record history version 3 · last update posted 2026-07-07 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 26ClinicalTrials.gov record NCT07843472 · retained source version 2026-10-07:b4d7f3eecf4b6c9a8842198319f5d5c3a421bf03ca09434d4d315fdacfc97697 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 27ClinicalTrials.gov record NCT07843485 · retained source version 2026-11-05:e5fd0540362d59efc4e0e476ab3f05c74427735d5576cee67cbafed4c6f394d5 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 28ClinicalTrials.gov record NCT07843498 · retained source version 2026-11-05:9b532d149aaffed6b38bd85ef1731c2342003d62a19554586ffc692016cb1e62 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 29Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 30ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 31BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 32ClinicalTrials.gov record NCT07754461 · retained source version 2026-08-10:d71d6065261ae9f1c83fbc9694b2dc6cef63964c1377569876a214c0a75eb88e ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 33Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study (2026) · PMID 41508550 ↗
Obesity · Official source · Source checked November 16, 2026
- 34ClinicalTrials.gov record NCT07868835 · retained source version 2026-11-16:754cc17245a18215ce0d3940312a9a7ada00032d9098c9032f6a189cf2f02123 ↗
ClinicalTrials.gov · Official source · Source checked November 16, 2026
- 35IMPACT: Pemvidutide in Participants With NASH · record history version 10 · last update posted 2026-05-18 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 36ClinicalTrials.gov record NCT07795164 · retained source version 2026-08-31:445923515599b1c75e5a12a2ec64209d4453be7d93d0614bca15d8035020d448 ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026
- 37Apraglutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 38STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure (2026) · PMID 42692160 ↗
Clinical Gastroenterology and Hepatology · Official source · Source checked November 15, 2026
- 39Glepaglutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 40Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial (2025) · PMID 39708985 ↗
Gastroenterology · Official source · Source checked November 15, 2026
- 41Larazotide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 42Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial (2015) · PMID 25683116 ↗
Gastroenterology · Official source · Source checked November 15, 2026
- 43Cibinetide (ARA 290) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 44Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (2017) · PMID 28475703 ↗
Investigative Ophthalmology & Visual Science · Official source · Source checked November 15, 2026
- 45Aviptadil substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 46Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial (2023) · PMID 37348524 ↗
The Lancet Respiratory Medicine · Official source · Source checked November 15, 2026